Open Trials at PCC

Open Trials at Pacific Cancer Care

Our research staff is always happy to speak with you and help you make an informed decision about volunteering for a clinical trial. If you have any questions or are interested in participating in one of our clinical trials, please call us at 831-375-4105.

Breast Cancer
NCT #03523585
Destiny: A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

Gastric or Gastroesophageal Junction (GEJ)
NCT #03653507
Glow: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric or Gastroesophageal Junction (GEJ)
NCT # 03615326
Keynote-811: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants with HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction (GEJ)
NCT # 04014075
A Phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS-8201a) in HER2-positive, unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen

Hematologic Malignancies
NCT #03598608
MK4280-003: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab in Participants with Hematologic Malignancies

Multiple Myeloma
NCT #03110822
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients

Multiple Myeloma
NCT # 03984097
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy

Non-Hodgkin’s Lymphomas
NCT #03893682
Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas

Non-Small Cell Lung Cancer
NCT #03425643
KEYNOTE-671: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

Prostate Cancer
NCT # 02152631
JPCM: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

Triple Negative Breast Cancer and Bladder Cancer
NCT # 03961698
MARIO-3: A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

Urothelial Carcinoma
NCT # 03788746
PREVAIL: A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma


Blood Cancer Research Partnership with Dana-Farber Cancer Institute 

High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT #03236428
Pilot Study of the CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma


Through partnerships with organizations such as the Dana Farber Cancer Institute and Parker Institute for Cancer Immunotherapy, our patients rest assured knowing that a full complement of research and clinical resources are available to them, all synchronized and supervised by their Pacific Cancer Care team.